FGF21 and metabolic dysfunction-associated steatotic liver disease: Moreover, the interference of the FGF21–mechanistic target of rapamycin complex 1 axis reduces chronic NAFLD via stimulation of FGF21 kinase, suggesting that the FGF21 pathway may be a potential therapeutic target for NAFLD [22].